Molecular analysis of the structure and function of the angiotensi II type 1 receptor

Hypertension Research

Volumn 26, Issue 12, 2003, Pages 937-943

  Miura, Shin Ichiro ^a,b   Saku, Keijiro ^a   Karnik, Sadashiva S ^b  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Angiotensin II type 1 receptor; G protein coupled receptors; Structure and function

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; CELL PROTEIN; G PROTEIN COUPLED RECEPTOR; MEMBRANE RECEPTOR; RECEPTOR SUBTYPE;

AMINO ACID SEQUENCE; CELLULAR DISTRIBUTION; CHEMISTRY; CONGESTIVE HEART FAILURE; DRUG TARGETING; GENETICS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTERNALIZATION; ISCHEMIC HEART DISEASE; MEDICAL GENETICS; METABOLISM; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ANGIOTENSIN, TYPE 1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642422252     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.937     Document Type: Review

References (54)

1. George SR, O'Dowd BF, Lee SP: G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-820.
2. Hein L, Meinel L, Pratt RE, et al: Intracellular trafficking of angiotensin II and its AT1 and AT2 receptors: evidence for selective sorting of receptor and ligand. Mol Endocrinol 1997; 11: 1266-1277.
3. Boivin B, Chevalier D, Villeneuve LR, et al: Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes. J Biol Chem 2003; 278: 29153-29163.
4. Costa T, Ogino Y, Munson PJ, et al: Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 1992; 41: 549-560.
5. Schutz W, Freissmuth M: Reverse intrinsic activity of antagonists on G protein-coupled receptors. Trends Pharmacol Sci 1992; 13: 376-380.
6. Ango F, Prezeau L, Muller T, et al: Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature 2001; 411: 962-965.
7. Deng Fu G, Sun Y, Hamet P, et al: The angiotensin II type 1 receptor and receptor-associated proteins. Cell Res 2001; 11: 165-180.
8. de Gasparo M, Catt KJ, Inagami T, et al: International Union of Pharmacology: XXIII: the angiotensin II receptors. Pharmacol Rev 2000; 52: 415-472.
9. Hiroi Y, Hiroi J, Kudoh S, et al: Two distinct mechanisms of angiotensin II-induced negative regulation of the mitogen-activated protein kinases in cultured cardiac myocytes. Hypertens Res 2001; 24: 385-394.
10. Horiuchi M, Hamai M, Cui TX, et al: Cross talk between angiotensin II type 1 and type 2 receptors: cellular mechanism of angiotensin type 2 receptor-mediated cell growth inhibition. Hypertens Res 1999; 22: 67-74.
11. Miyazaki M, Takai S: Local angiotensin II-generating system in vascular tissues: the roles of chymase. Hypertens Res 2001; 24: 189-193.
12. Holloway AC, Qian H, Pipolo L, et al: Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol 2002; 61: 768-777.
13. Miura S, Karnik SS: Ligand-independent signals from angiotensin II type 2 receptor induce apoptosis. EMBO J 2000; 19: 4026-4035.
14. Jin XQ, Fukuda N, Su JZ, et al: Angiotensin II type 2 receptor gene transfer downregulates angiotensin II type 1a receptor in vascular smooth muscle cells. Hypertension 2002; 39: 1021-1027.
15. AbdAlla S, Lother H, Quitterer U: AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 2000; 407: 94-98.
16. AbdAlla S, Lother H Abdel-Tawab AM, et al: The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 2001; 276: 39721-39726.
17. Gether U: Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21: 90-113.
18. Peleg G, Ghanouni P, Kobilka BK, et al: Single-molecule spectroscopy of the β2 adrenergic receptor: observation of conformational substates in a membrane protein. Proc Natl Acad Sci USA 2001; 98: 8469-8474.
19. Timmermans PB: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res 1999; 22: 147-153.
20. Ichikawa S, Takayama Y: Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients. Hypertens Res 2001; 24: 647-653.
21. Saito I, Kawabe H, Tsujioka M, et al: Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines: First Japanese Society of Hypertension. Hypertens Res 2002; 25: 175-178.
22. Palezewski K, Kumasaka T, Hori T, et al: Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-745.
23. Yamano Y, Ohyama K, Chaki S, et al: Identification of amino acid residues of rat angiotensin II receptor for ligand binding by site-directed mutagenesis. Biochem Biophys Res Commun 1992; 187: 1426-1431.
24. Noda K, Saad Y, Kinoshita A, et al: Tetrazole and carboxylate groups of angiotensin receptor antagonists bind to the same subsite by different mechanisms. J Biol Chem 1995; 270: 2284-2289.
25. 281 of AT1 receptor is essential for full agonism. J Biol Chem 1995; 270: 12846-12850.
26. Le MT, Vanderheyden PM, Szaszak M, et al: Angiotensin IV is a potent agonist for constitutive active human AT1 receptors: distinct roles of the N- and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem 2002;277:23107-23110.
27. Lefkowitz RJ, Cotecchia S, Samama P, et al: Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14: 303-307.
28. Noda K, Feng YH, Liu XP, Saad Y, Husain A, Karnik SS: The active state of the AT1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 1996; 35: 16435-16442.
29. 256 of AT1 receptor in agonist activation. J Biol Chem 1995; 270: 28511-28514.
30. Monnot C, Bihoreau C, Conchon S, et al: Polar residues in the transmembrane domains of the type 1 angiotensin II receptor are required for binding and coupling: reconstitution of the binding site by co-expression of two deficient mutants. J Biol Chem 1996; 271: 1507-1513.
31. 111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation. J Biol Chem 1997; 272: 1822-1826.
32. Miura S, Feng YH, Husain A, et al: Mechanism of constitutive activation of the AT1 receptor: influence of the size of the agonist switch binding residue Asn(111). Biochemistry 1998; 37: 15791-15798.
33. Miura S, Feng YH, Husain A, et al: Role of aromaticity of agonist switches of angiotensin II in the activation of the AT1 receptor. J Biol Chem 1999; 274: 7103-7110.
34. Miura S, Karnik SS: Angiotensin II type 1 and type 2 receptors bind angiotensin II through different types of epitope recognition. J Hypertens 1999; 17: 397-404.
35. Marie J, Koch C, Pruneau D, et al: Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 1999; 55: 92-101.
36. Perez DM, Hwa J, Gaivin R, et al: Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol 1996; 49: 112-122.
37. Zuscik MJ, Porter JE, Gaivin R, et al: Identification of a conserved switch residue responsible for selective constitutive activation of the beta 2-adrenergic receptor. J Biol Chem 1998; 273: 3401-3407.
38. Miura S, Zhang B, Karnik SS: Angiotensin II type 1 receptor-function affected by mutations in cytoplasmic loop CD. FEBS Lett 2000; 470: 331-335.
39. Feng YH, Karnik SS: Role of transmembrane helix IV in G-protein specificity of the angiotensin II type 1 receptor. J Biol Chem 1999; 274: 35546-35552.
40. Teller DC, Okada T, Behnke CA, et al: Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001; 40: 7761-7772.
41. Menon ST, Han M, Sakmar TP: Rhodopsin: structural basis of molecular physiology. Physiol Rev 2001; 81: 1659-1688.
42. Inoue Y, Nakamura N, Inagami T: A review of mutagenesis studies of angiotensin II type 1 receptor, the three-dimensional receptor model in search of the agonist and antagonist binding site and the hypothesis of a receptor activation mechanism. J Hypertens 1997; 15: 703-714.
43. Ghanouni P, Steenhuis JJ, Farrens DL, et al: Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A 2001; 98: 5997-6002.
44. Miura S, Karnik SS: Constitutive activation of angiotensin II type 1 receptor alters the orientation of transmembrane helix-2. J Biol Chem 2002; 277: 24299-24305.
45. Miura S, Zhang J, Boros J, et al: TM2-TM7 interaction in coupling movement of transmembrane helices to activation of the angiotensin II type-1 receptor. J Biol Chem 2003; 278: 3720-3725.
46. Miura S, Saku K, Karnik SS: Selective signal transduction through AT1 receptor induced by angiotensin II. Circ J 2002; 66: 636 (Abstract).
47. Morisset S, Rouleau A, Ligneau X, et al: High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 2000; 408: 860-863.
48. Miura S, Ramchandran R, Chang CS, et al: Changes in cell cycle regulation during angiotensin II type 1 receptor-mediated cell growth. FASEB J 1999; 13: A1537 (Abstract).
49. Suzuki J, Ohta H, Hanada K, et al: Acute effects of E-3174, a human active metabolite of losartan, on the cardiovascular system in tachycardia-induced canine heart failure. Hypertens Res 2001; 24: 65-74.
50. Jordan BA, Devi LA: G-protein-coupled receptor heterodimerization modulates receptor function. Nature 1999; 399: 697-700.
51. Hebert TE, Loisel TP, Adam L, et al: Functional rescue of a constitutively desensitized beta 2AR through receptor dimerization. Biochem J 1998; 330: 287-293.
52. Maggio R, Barbier P, Fornai F, et al: Functional role of the third cytoplasmic loop in muscarinic receptor dimerization. J Biol Chem 1996; 271: 1055-1160.
53. Ng GY, OiDowd BF, Lee SP, et al: Dopamine D2 receptor dimers and receptor-blocking peptides. Biochem Biophys Res Commun 1996; 277: 200-204.
54. AbdAlla S, Lother H, El Massiery A, et al: Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7: 1003-1009.